No relation between cystic fibrosis–related diabetes and type 1 diabetes autoimmunity

PA Gottlieb, L Yu, S Babu, J Wenzlau, M Bellin… - Diabetes …, 2012 - Am Diabetes Assoc
PA Gottlieb, L Yu, S Babu, J Wenzlau, M Bellin, BI Frohnert, A Moran
Diabetes Care, 2012Am Diabetes Assoc
Diabetes is the most common comorbidity in individuals with cystic fibrosis. The etiology is
poorly understood. Data on the presence of diabetes autoantibodies are conflicting, and little
is known about type 1 diabetes gene associations. Our goal was to determine the
prevalence of antibodies and HLA haplotypes known to be associated with type 1 diabetes
in cystic fibrosis–related diabetes (CFRD). Patients with CFRD with fasting hyperglycemia
were recruited from the University of Minnesota. Serum for antibodies and buffy coats for …
Diabetes is the most common comorbidity in individuals with cystic fibrosis. The etiology is poorly understood. Data on the presence of diabetes autoantibodies are conflicting, and little is known about type 1 diabetes gene associations. Our goal was to determine the prevalence of antibodies and HLA haplotypes known to be associated with type 1 diabetes in cystic fibrosis–related diabetes (CFRD).
Patients with CFRD with fasting hyperglycemia were recruited from the University of Minnesota. Serum for antibodies and buffy coats for HLA were sent for analysis to the Barbara Davis Center for Childhood Diabetes (BDC). All patients gave informed consent. The Eisenbarth laboratory at BDC serves as the autoantibody/HLA reference laboratory for large national diabetes studies. Insulin, insulinoma-associated protein 2 (IA-2), GAD65, and zinc transporter 8 (ZnT8) autoantibodies were measured by radioimmunoassay (1, 2). HLA class II alleles were determined for DQB1 loci (3). Comparison data were obtained from new-onset diabetes and population studies collected at BDC (1–3). Of 76 CFRD patients, 50% were female, the average age was 34 years (range 15–55), and the average duration of diabetes was 10 years (range 1–33). All received constant or intermittent insulin therapy. In the general population,; 2% of individuals are positive for one of IA-2, GAD, ZnT8, or insulin autoantibodies (1). In contrast, 55–98% of individuals with
Am Diabetes Assoc